GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » Gross Margin %

NervGen Pharma (STU:9UA) Gross Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is NervGen Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. NervGen Pharma's Gross Profit for the three months ended in Sep. 2024 was €0.00 Mil. NervGen Pharma's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, NervGen Pharma's Gross Margin % for the quarter that ended in Sep. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for NervGen Pharma's Gross Margin % or its related term are showing as below:


STU:9UA's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.565
* Ranked among companies with meaningful Gross Margin % only.

NervGen Pharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for NervGen Pharma was 0.00% per year.


NervGen Pharma Gross Margin % Historical Data

The historical data trend for NervGen Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Gross Margin % Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NervGen Pharma's Gross Margin %

For the Biotechnology subindustry, NervGen Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's Gross Margin % falls into.



NervGen Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

NervGen Pharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

NervGen Pharma's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


NervGen Pharma  (STU:9UA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

NervGen Pharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


NervGen Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma Business Description

Comparable Companies
Traded in Other Exchanges
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

NervGen Pharma Headlines

No Headlines